Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.
Invest New Drugs
; 38(4): 1186-1191, 2020 08.
Article
in En
| MEDLINE
| ID: mdl-31637668
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyridines
/
Protein-Tyrosine Kinases
/
Uterine Cervical Neoplasms
/
Angiogenesis Inhibitors
/
Protein Kinase Inhibitors
/
Neoplasm Recurrence, Local
/
Neovascularization, Pathologic
Limits:
Adult
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2020
Document type:
Article